Oasmia recruits a new CFO

The Uppsala-based pharmaceutical company Oasmia Pharmaceutical AB (publ), listed on Nasdaq OMX, has employed Anders Lundin as its new CFO.

        Print
| Source: Oasmia Pharmaceutical AB
multilang-release

Uppsala, Sweden, 2014-05-15 08:59 CEST (GLOBE NEWSWIRE) --  

Anders last employment was as Head of Finance at Q-Med in Uppsala. He has 21 years’ experience in business administration of commercial businesses. Among others, he had been employed as Finance Manager at GE Healthcare, Zarlink Semiconductor, Hi3g Access AB and Elektronikgruppen AB. Anders has a Bachelor degree in Business Administration from Uppsala University. 

The employment begins on August 11, 2014. 

For more information, please contact:
 

Notes to editors: 

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics, which, in comparison with current alternatives, show improved properties, reduced side effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

         Mikael Widell, Vice President Communications
         Mobile: +46 70 311 99 60
         E-mail: mikael.widell@oasmia.com
         www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia